SOFIVA GENOMICS Co (ROCO:6615) ROCE % : -1.39% (As of Dec. 2024)

View and export this data going back to 2017. Start your Free Trial

What is SOFIVA GENOMICS Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. SOFIVA GENOMICS Co's annualized ROCE % for the quarter that ended in Dec. 2024 was -1.39%.

SOFIVA GENOMICS Co ROCE % Historical Data

The historical data trend for SOFIVA GENOMICS Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SOFIVA GENOMICS Co ROCE % Chart

SOFIVA GENOMICS Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROCE %

Get a 7-Day Free Trial

6.26

9.76

7.02

1.50

3.65

SOFIVA GENOMICS Co Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROCE %	Get a 7-Day Free Trial															-1.93	8.69	6.59	0.76	-1.39

SOFIVA GENOMICS Co ROCE % Calculation

SOFIVA GENOMICS Co's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	24.726	/	( ( (767.138 - 96.198)	+	(768.083 - 83.457) )	/ 2 )
	=	24.726	/	( (670.94	+	684.626)	/ 2 )
	=	24.726	/	677.783
	=	3.65 %

SOFIVA GENOMICS Co's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	-9.604	/	( ( (776.491 - 83.345)	+	(768.083 - 83.457) )	/ 2 )
	=	-9.604	/	( ( 693.146	+	684.626 )	/ 2 )
	=	-9.604	/	688.886
	=	-1.39 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

SOFIVA GENOMICS Co (ROCO:6615) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

SOFIVA GENOMICS Co ROCE % Related Terms

Thank you for viewing the detailed overview of SOFIVA GENOMICS Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

SOFIVA GENOMICS Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » SOFIVA GENOMICS Co Ltd (ROCO:6615) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 66-1, Sec. 1, Chongqing S. Road, 4th Floor, Zhongzheng District, Taipei, TWN, 10043

Website

https://www.sofivagenomics.com.tw

SOFIVA GENOMICS Co Ltd provides medical diagnostic services. The services offered by the company include Prenatal, Reproductive, Cancer, Precision medicine, Newborn, and Rare Diseases. Its testing categories include Genetic, Biochemical, and Chromosome. The business items of Sofiva Group are pre-pregnancy, pre-natal and neonatal genetic testing and medical testing and other service income. Geographically, it generates the vast majority of its revenue from Taiwan.

SOFIVA GENOMICS Co Headlines

No Headlines